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Abstract
Purpose of Review Prosthetic joint infection (PJI) remains a serious concern in lower limb arthroplasty. Despite the significant
consequences of PJI, the assessment of the safety and efficacy of preventative measures is challenging due to a low event rate.
Notwithstanding, enormous efforts have been made in this arena, and prevention strategies continue to evolve. This review
provides an update on contemporary literature (published within the last 5 years) pertaining to infection prevention in primary hip
and knee arthroplasty.
Recent Findings Patient optimization has been highlighted as a critical preoperative factor in mitigating PJI risk. Recent evidence
emphasizes the importance of preoperative glycaemic control, nutritional status, weight optimization and smoking cessation prior
to hip and knee arthroplasty. Perioperatively, attention to detail in terms of surgical skin preparation agent and technique as well
as prophylactic antibiotic agent, spectrum, dose and timing is important with statistically and clinically significant differences
seen between differing strategies. Intraosseous regional antibiotic administration is an emerging technique with promising
preclinical data. Dilute betadine lavage also shows promise. Data supporting bundled interventions continues to grow.
Summary A multimodal approach is required in PJI prevention, and attention to detail is important with each element. Patient
optimization is critical, as is the execution of the planned perioperative infection prevention strategy.
Keywords Arthroplasty . Hip . Knee . Infection . Prevention
Introduction
Infection prevention is a critical component in optimizing
lower limb arthroplasty outcomes. Risk stratification is impor-
tant for preoperative counselling, as is a structured approach in
mitigating modifiable risk factors. This review provides an
update and overview of contemporary literature pertaining to
infection prevention in hip and knee arthroplasty divided into
preoperative, perioperative and post-operative considerations.
Preoperative Strategies
Screening and Threshold for Acceptable Preoperative
Glycaemic Control
For diabetic patients, assessment of glycaemic control has
long been considered important in risk stratification and pre-
vention of prosthetic joint infection (PJI) [1]. The ideal marker
of glycaemic control and threshold where PJI risk is increased
continue to be refined. Cancienne et al. [2] queried a national
administrative database and identified a group of 7736 pa-
tients undergoing total hip replacement (THR) who had a
haemoglobin A1c (HbA1c) level within 3 months of surgery.
HbA1c levels were stratified in 0.5 mg/dL increments, and the
incidence of deep infection within 1 year of surgery was cal-
culated for eachHbA1c stratification. An exponential relation-
ship between HbA1c and infection rate was demonstrated.
Patients with an HbA1c level of 7.5 mg/dL or greater had a
significantly higher risk of deep infection compared with pa-
tients below this threshold (odds ratio (OR) 2.6, p < 0.0001).
A receiver operator characteristic inflexion point
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corresponded to a HbA1c level between 7.0 and 7.5 mg/dL
(p = 0.001, specificity 69%, sensitivity 47%). A similar HbA1c
threshold of 7.7 mg/dL was suggested by Tarabichi et al. [3]
after conduction of a multicentre retrospective study of 1645
diabetic patients undergoing hip and knee arthroplasty. With
the primary outcome of PJI at 1 year diagnosed by
Musculoskeletal Infection Society (MIS) criteria, a HbA1c over
7.7 mg/dL was predictive of PJI (area under the curve, 0.65;
95% CI, 0.51–0.78). Using this threshold as a cut off, PJI rates
increased from 0.8% (11 of 1441) to 5.4% (11 of 204).
A growing evidence base supports serum fructosamine as
an alternate, potentially superior measure of preoperative
glycaemic control. Shohat et al. [4] reported on 829 patients
undergoing primary total joint arthroplasty from a prospec-
tively collected database. A serum fructosamine >
292 mmol/L outperformed a HbA1c > 7% in predicting deep
infection, readmission and reoperation. Shohat et al. [5•] later
reported results of a prospective multi-institutional study eval-
uating primary TKA patients from four academic institutions.
PJI and wound complication were assessed in 1119 patients.
Patients with serum fructosamine > 293 μmol/l were 11.2
times more likely to develop PJI compared with patients with
fructosamine < 293 μmol/l (p = 0.001). Readmission and re-
operation rates were 4.2 and 4.5 times higher in patients with
fructosamine above this threshold. HbA1c at a threshold of
5.9%, 7% or 7.5% was unable to identify patients at higher
risk of these complications. The authors concluded that serum
fructosamine is better able to predict adverse events as com-
pared with HbA1c in arthroplasty patients.
Identification and Optimization of Perioperative
Malnutrition
Malnutrition has a spectrum of severity and can be difficult to
diagnose. It can be subclinical and has been demonstrated to
be common even in the setting of obesity [6]. There has been
recent interest in the use of biochemical markers as a surrogate
for nutritional status in joint replacement patients. Blevins
et al. [7] conducted a retrospective investigation into the rela-
tionship between abnormal nutritional parameters and devel-
opment of PJI as diagnosed by MIS criteria. Over a 16-year
period, 30,863 patients undergoing hip or knee arthroplasty
were assessed for PJI at 2 years. Multivariate logistic regres-
sion analysis demonstrated albumin < 3.5 g/dL (adjusted OR,
4.69, p < .001) and haemoglobin < 12 g/dL (adjusted OR,
2.718, p = 0.018) were independently associated with PJI, al-
though albumin data were only available for 9001 patients.
Similar findings were reported by Bohl et al., [8] who inves-
tigated the association between preoperative hypoalbumin-
emia (< 3.5 g/dL) and 30-day complication rates in 49,603
primary arthroplasties. After adjusting for demographic, co-
morbid i ty and labora tory fac tors , pa t ients wi th
hypoalbuminemia were at higher risk for SSI (2.29% vs
0.96%; adjusted relative risk (RR) 2.0, p = 0.001).
The efficacy of delaying arthroplasty to allow for nutritional
optimization remains to be tested in clinical trials. However, in a
2016 review, Golladay et al. [9] made recommendations for
arthroplasty patients on the basis of the existing arthroplasty
and non-arthroplasty literature. The authors suggested the most
common serologic markers to indicating preoperative malnutri-
tion included a serum albumin of less than 3.5 g/dL, absolute
lymphocyte count of less than 1500 and transferrin < 200. The
authors recommended consideration of some simple preoperative
interventions prior to arthroplasty (Table 1).
Management of the Patient with Obesity
Obesity has long been associated with increased perioperative
complications in patients undergoing total joint replacement
(TJR). Preoperative bariatric surgery is one potential interven-
tion that has been investigated to mitigate this risk. A 2019
meta-analysis by Li et al. [10] investigated the influences of
prior bariatric surgery on TJR outcomes in patients with a
BMI > 40 kg/m2. The primary outcome of interest was com-
plication (including PJI) and revision rates. Across 9 studies, a
total of 38,728 patients were included with 5743 patients un-
dergoing bariatric surgery prior to TJA and 32,985 morbidly
obesity patients having TJA without bariatric surgery. The
mean BMI prior to TJA in the control group was above 40,
while it was below 40 in the bariatric surgery group. Six stud-
ies reported short-term (within 90 days) PJI rates. The bariatric
surgery group tended to have a lower rate of PJI, with 159 of
5434 patients (2.9%) in this group and 1110 of 21,768 patients
(5.1%) in the non-bariatric surgery group developing PJI (OR
0.70, p = 0.09). Although this difference was not significant,
on subgroup analysis, a significant reduction in the risk of
short-term PJI was seen in the bariatric surgery group under-
going TKA (OR 0.51, p = 0.0009). This was not evident for
THA (OR 0.93, p = 0.52). Two of the included studies report-
ed on short-term superficial wound infection; five of 237
Table 1 Considerations for nutritional optimization in arthroplasty
patients as proposed by Golladay et al.
Nutritional element Intervention/supplementation
Protein Protein supplement, 1 g/kg daily for 10–14 days
Iron 324 mg TDS for 3–4 weeks
Vitamin D 1000 IU daily (increase if deficient)
Vitamin C 500 mg daily for 2 weeks
Zinc sulphate 220 mg daily
TDS three times per day IU international units
Table adapted from Golladay GJ, Satpathy J and Jiranek WA. Patient
optimization—strategies that work: malnutrition. The Journal of
arthroplasty. 2016;31(8):1631-4
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knees (2.1%) in the bariatric surgery group and 42 of 11,068
patients (0.4%) in non-bariatric surgery group developed a
superficial wound infection. The difference was not signifi-
cant (OR 3.25, p = 0.07). Long-term (follow-up > 1 year) PJI
rates were reported in 6 studies. There was no significant
difference between groups, with 107 of 2006 patients (5.3%)
in the bariatric surgery group and 612 of 18,210 patients
(3.4%) in the non-bariatric surgery group developing PJI
(OR 0.93, p = 0.54). The meta-analysis was limited by the
heterogeneity of the included studies and smaller numbers
for subgroup analyses. No recommendations were made in
relation to when preoperative bariatric surgery should be con-
sidered. Optimal timing between bariatric surgery and TJR
also need to be defined. The latter question was addressed in
a study by Schwarzkopf et al. [11]. Patients undergoing THA
more than 6 months after bariatric surgery were significantly
less likely to be readmitted within 90 days for any cause;
however, infection rates were not reported on. A further
2019 systematic review and meta-analysis on the efficacy of
pre-arthroplasty bariatric surgery by Gu et al. [12] did not
report rates of infection in isolation.
Arthroplasty After Intra-articular Injection
Using a nationwide insurance database, Richardson et al. [13•]
assessed 58,337 patients undergoing primary TKR to assess
the impact of preoperative corticosteroid or hyaluronic acid
(HA) injections on the 6-month risk of PJI. Three thousand
two hundred forty-nine patients (5.6%) received HA, and
16,656 patients (28.6%) received corticosteroid injections
within the year prior to TKR. Multivariable logistic regression
showed both corticosteroid (OR 1.21; p = 0.014) and HA
(OR, 1.55; p = 0.029) given < 3 months of TKR were predic-
tors of PJI independent of age, sex or comorbidities. There
was no increased risk with injections > 3 months prior to
TKR. There was no difference in PJI rates when based on type
of injection (corticosteroid versus HA) or between single ver-
sus multiple injections. This large cohort adds to existing stud-
ies supporting delaying TKR for 3 months after intra-articular
injection [14], although some series have suggested the infec-
tion risk may be elevated for as long as 6 months [15].
Smoking Status and Cessation
A 2019 meta-analysis by Bedard et al. [16] examined the
effects of smoking status on PJI in hip and knee arthroplasty
patients. Fourteen studies reporting on 227,289 primary THA
and TKAwere included in the meta-analysis. Strengths of this
meta-analysis include assessment of overall wound complica-
tions as well as PJI specifically and the assessment of non-
smoker, ex-smoker and current smoker groups. Weaknesses
include the quality of the included studies which were com-
prised of entirely retrospective series with associated biases
and heterogeneity. Nonetheless, the authors demonstrated that
smokers had a significantly higher risk of both overall wound
complications (OR 1.78) and PJI (OR 2.02). Compared with
non-smoker users, there was an increased risk of PJI in both
current smokers (OR 2.16) and former smokers (OR 1.52);
however, only 6 and 10 of the studies reported on these
groups, respectively. Current tobacco users also had a signif-
icantly increased risk of PJI compared with former tobacco
users (OR 1.52). The study was unable to determine an opti-
mum time frame between smoking cessation and arthroplasty
surgery. No studies were identified that reported PJI rates after
interventions to quit smoking.
Intraoperative Strategies
Selection of Surgical Skin Site Preparation
Peel et al. [17•] conducted a cluster randomized, assessor-
blinded, superiority trial in patients undergoing elective TJR
comparing chlorhexidine gluconate 0.5% in 70% ethanol to
1% iodine in 70% ethanol. At a university teaching hospital,
780 participants were included with 390 participants random-
ized to each group. Standard preoperative protocols included
MRSA screening and eradication, preadmission chlorhexidine
body wash, urine screening and prophylactic antibiotics. The
primary outcome was superficial incisional SSI and/or clini-
cally significant wound ooze within 30 days. The secondary
outcome was any surgical site infection, including PJI. There
was no difference in the rate of superficial wound complica-
tions (4.9% vs 3.8%, p = 0.50). There was, however, an in-
creased rate of SSI in the chlorhexidine alcohol group com-
pared with iodine alcohol (3.1% vs 1.0%, p = 0.014). The
odds of PJI were also increased in the chlorhexidine alcohol
arm compared with iodine alcohol (1.8% vs 0.5%, p = 0.022).
The authors concluded that alcohol-based iodophor prepara-
tions are a reasonable choice for surgical site skin preparation.
Contradictory findings from a recent World Health
Organization meta-analysis in the non-arthroplasty population
were acknowledged by the authors [18]. Selection of
chlorhexidine-tolerant bacteria due to the pre-hospital body
wash or a potential preferential role for iodine alcohol for
procedures involving implantation of prosthetic material was
hypothesized as explanations by the authors.
Single Versus Repeat Surgical Site Skin Preparation
In a randomized control trial of 600 patients undergoing TKR
or THR, Morrison et al. [19] investigated the effect of repeat
surgical site skin preparation on the incidence of surgical site
infection. Both groups were initially prepped with a 7.5%
povidone-iodine scrub, 75% isopropyl alcohol and then 10%
iodine paint. In addition, the intervention group received an
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additional preparation of iodine povacrylex and isopropyl al-
cohol over the incision site prior to adhesive draping. Mean
follow-up was in excess of 37 months for both groups. There
was a significant reduction in the incidence of superficial SSI
for the intervention group (1.8% vs 6.5%, p = 0.02). Similar
rates of PJI were reported between groups (0.7% vs 0.7%, p =
1.00). The authors recommend that a second surgical prepa-
ration solution be applied to the skin after draping and before
making a surgical incision.
Knee Flexion Angle During Surgical Site Skin
Preparation
Knoll et al. [20] describe a skin preparation technique where
the knee is positioned in maximum flexion to allow superior
exposure of the extensor surface. A case example highlighted
inadequate skin preparation being revealed upon knee flexion
when the limb had been prepped in extension. The authors
acknowledge a lack of objective evidence demonstrating a
decreased rate of surgical site infection associated with this
technique and, however, emphasize a low institutional infec-
tion rate of under 1%.
Intra-articular Dilute Betadine Lavage
Brown et al. [21] investigated the effects of a 500 ml, 0.35%
betadine lavage for 3 min on the 90-day incidence of deep infec-
tion following hip and knee arthroplasty in a before and after
comparative study. A retrospective cohort of 1862 consecutive
patients (630 THA, 1232 TKA) was compared with a prospec-
tive cohort of 688 consecutive patients (274 THA, 414 TKA)
following introduction of this protocol. The betadine lavage
group also had betadine applied to the skin surrounding the in-
cision which was not done in the control group; however, both
groups had a 1 L normal saline pulse lavage prior to closure.
Patient demographics in each group were similar. Eighteen early
post-operative infections were identified before the use of dilute
betadine lavage, and 1 was identified following (0.97% vs
0.15%, p= 0.04).
The senior author from the paper by Brown et al. [21] later
reported results of a randomized control trial investigatingwheth-
er the same protocol reduces the rate of acute post-operative
periprosthetic joint infection in aseptic revision hip and knee
arthroplasty [22]. Although the focus of this review is on primary
arthroplasty, this trial adds to the emerging evidence for the effi-
cacy of this strategy which potentially applies in the primary
arthroplasty setting also. Patients were randomized to either
0.35% dilute betadine lavage for 3 min (144 knees, 79 hips) or
normal saline lavage (153 knees, 81 hips). Operative procedures
and patient demographics were similar between the randomized
groups. Within 90 days post-operatively, there were eight infec-
tions in the saline group and 1 in the betadine group (3.4% vs
0.4%, p = 0.038). There was no difference in wound
complications between groups (1.3% vs 0%, p = 0.248). Of note,
the senior author does not use dilute betadine lavage when
performing unicompartmental knee arthroplasties due to con-
cerns of the impact on the articular cartilage in the non-
resurfaced joint compartments.
Glove Changing
As highlighted in a 2019 systematic review by Kim et al. [23],
evidence regarding the efficacy of intraoperative glove chang-
ing to reduce the risk of PJI in arthroplasty surgery remains
weak. The search found no data measuring a direct effect of
glove change on PJI rate. The authors therefore summarized
the available literature examining glove microbiological con-
tamination and perforation rate as a surrogate marker. Eight
studies evaluated microbiological contamination of surgical
gloves, with rates ranging from 3.4 to 30%. Two of these
studies were randomized trials. Pooled results of these two
studies showed reduced contamination rates in the glove
change group (OR 0.37, p < 0.0001). Acknowledging the lim-
itations of the available data, the authors concluded that
changing gloves significantly reduces contamination rates.
Based on this, the authors recommend gloves should be
changed after draping, before handling implants, if visible
perforation is seen as well as every hour if the aforementioned
criteria are not met.
Body Exhaust Suits and Surgical Helmet Systems
A 2016 systematic review by Young et al. [24] evaluated the
efficacy of body exhaust suits (BES) and surgical helmet sys-
tems (SHS) as compared with conventional surgical gowns in
arthroplasty infection prevention. The authors differentiated
between the 2 systems highlighting that BES are characterized
by aspiration tubing and a negative intra suit pressure, while
SHS are typically characterized by a fan on a helmet with a
positive pressure within the suit. The authors acknowledged
differing designs, materials, constructions and filtering sys-
tems amongst the various SHS available. Four studies total-
ling 3990 patients compared PJI rates between BES and con-
ventional surgical gowns. At a mean 2.5-year follow-up, PJI
rates were 0.17% (3 of 1795) in the BES group and 1.0% (16
of 1604) in the conventional surgical gown group (p < 0.01).
Three registry-based investigations including 175,018 patients
compared deep infection rates between SHS and conventional
surgical gowns. SHS was associated with an increase in deep
infections (RR 1.67) after adjustment for major covariates;
however, this was not statistically significant (p = 0.09). The
authors concluded that “In contrast to BES, modern SHS de-
signs were not shown to reduce contamination or deep infec-
tion during arthroplasty”.
Vijaysegaran et al. [25] proposed a mechanism by which
infection rates may be increased in association with SHS. An
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airtight flow through chamber was used as a simulated surgi-
cal environment. The authors compared the particle and mi-
crobiological emission rates of space suits and standard surgi-
cal attire. Particle and microbiological emission rates were
detected using an optical particle counter and an ultraviolet
aerodynamic particle sizer. The authors demonstrated that in
4 of the 5 experiments performed, there was a statistically
significant increase in both particle and microbiological emis-
sion rates when SHS are used compared with standard attire.
Antibiotic Administration
The optimal choice, timing and dose of prophylactic antibiotic
remain to be determined. Data regarding risks and benefits of
alternate and extended spectrum prophylaxis continues to
grow. Wyles et al. [26•] examined the effect of substituting a
first-generation cephalosporin for an alternate antibiotic (van-
comycin or clindamycin) due to allergy. Between January
2004 and May 2017, 29,695 arthroplasties were performed
with 28,174 (94.9%) received cefazolin and 1521 (5.1%) re-
ceived non-cefazolin antibiotics. The PJI rate was 32% lower
in patients given cefazolin after adjusting for ASA score and
BMI (p < 0.001). Survivorship free of PJI in the cefazolin
group compared with the non-cefazolin groups was 99.40%
vs 99.34% at 1 month, 99.11% vs 98.55% at 2 months,
98.83% vs 98.22% at 1 year, and 98.15% vs 96.96% at
10 years. The authors commented that the early divergence
was supportive of the efficacy of a first-generation cephalo-
sporin perioperatively. Cross-referencing their institutional
Allergy Testing Registry, 2576 patients were tested for a pa-
tient provided history of penicillin or cephalosporin allergy.
Of these, 96.8% were cleared by the allergist to use
cephalosporins.
The role of extended spectrum antibiotics such as the ad-
dition of vancomycin continues to be debated. Burger et al.
[27] demonstrated that when vancomycin is added, timing of
administration is important. One thousand nine hundred
seventy-seven consecutive primary TJR patients were
reviewed retrospectively with 1044 given cefazolin and 953
given cefazolin with a single dose of vancomycin.
Vancomycin administrationwas surgeon dependent and either
given selectively to high-risk patients or as standard. All pa-
tients received 1 g. The addition of a single dose of vancomy-
cin did not significantly reduce PJI rates when compared with
cefazolin alone (1.6% vs 2.1%, p = 0.32). However, when
initiated 45 min or earlier before incision, the infection rate
was lower (0.2%) when compared with cefazolin and vanco-
mycin within 45 min of incision (2.9%, p < 0.01) or to
cefazolin alone (2.1%, p < 0.01). The addition of vancomycin
is not without risk. Courtney et al. [28] retrospectively evalu-
ated 1828 patients undergoing primary TJA over a 2-year
period who received cefazolin (n = 500) or cefazolin and van-
comycin (n = 1328). Patients receiving vancomycin were
more likely to develop an acute kidney injury (AKI) compared
with those receiving cefazolin alone (13% vs 8%, p = 0.002).
The chance of a higher severity AKI was also greater in the
vancomycin group (3% vs 0%, p = 0.003). There was no dif-
ference in the rate of SSI surgical site (1.4% vs 1.1%, p =
0.636) in this study.
Kheir et al. [29] highlighted the importance of appropriate
weight-based dosage of vancomycin. They reviewed 1828
patients given prophylactic vancomycin prior to TJA. This
choice of antibiotic prophylaxis was made due to penicillin
allergy or MRSA colonization. Only 28% (518 of 1828) were
adequately dosed according to weight-based dosage recom-
mendations of 15 mg/kg. Ninety-four percent (1726 of
1828) of patients received a fixed 1-g dose of vancomycin,
and of these, 64% (1105 of 1726) were underdosed. Of the
patients who were underdosed with vancomycin, 2 of 20 PJI
were caused by MRSA. No patients with appropriate or
overdosed vancomycin developed PJI with MRSA. Similar
findings regarding underdosing have been reported in relation
to cefazolin dosing. Rondon et al. [30] assessed adequacy of
dosing of cefazolin based on guidelines for 1 g if a patient
weighs less than 60 kg, 2 g if patient weights between 60 kg
and 120 kg and 3 g if patient weight over 120 kg. Of 17,393
primary total joint arthroplasties, the vast majority of patients
weighing greater than 120 kg were underdosed (95.9%, 944/
984). Underdosed patients had a higher rate of 1-year PJI
compared with adequately dosed patients (1.51% vs 0.86%,
p = 0.002).
Bosco et al. [31] retrospectively reviewed their SSI rates
before and after routine-extended gram-negative antibiotic
prophylaxis to THR patients in response to high proportions
of gram-negative organisms in their PJI patients. Before
July 2012, all patients were administered 1 g of cefazolin,
and after this period, gentamicin or aztreonam was given in
addition. Of 5389 primary THR, 4122 received cefazolin on-
ly, and 1267 were given weight-based high-dose gentamicin
in addition. The SSI rate dropped from 1.19 (49/4122) to
0.55% (7/1267) (p = 0.05). During the study period, there
was no change in TKR SSI rates which were not given ex-
tended gram-negative prophylaxis.
Duration of Antibiotic Prophylaxis
Determining the optimum duration of antibiotic prophylaxis
after arthroplasty remains challenging. A 2019 meta-analysis
by Siddiqi et al. [31] investigated the efficacy of single-dose
preoperative antibiotic administration with or without extend-
ed post-operative prophylaxis. The primary outcome was SSI/
PJI within 2 years. Thirty-two studies including 23 random-
ized controlled trials were included reporting on 51,627 pa-
tients. The pooled effect for the comparison between a single
preoperative dose versus additional post-operative prophylax-
is was 0.96 (95% CI, 0.73 to 1.26). Despite the large numbers
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of included patients, the authors felt the analysis was “drasti-
cally underpowered” and that definitive conclusions could not
be drawn. They noted an overall poor quality of the included
studies. Eight studies compared post-operative antibiotics giv-
en for < 24 h versus > 24 h. There was no significant differ-
ence in infection rates between these subgroups with rates of
2.2% (56 of 2498) vs 1.3% (41 of 3080) respectively (p =
0.36). Similar findings were reported in another 2019 meta-
analysis examining efficacy of post-operative antibiotics is
any orthopaedic procedure where an implant was placed [32].
In a retrospective cohort study examining 2181
arthroplasties, Inabathula et al. [33] investigated whether ex-
tended oral antibiotic prophylaxis reduced PJI in high-risk
patients. Classification as high risk was determined at a coor-
dinated care conference based on factors including BMI > 35,
diabetes, smoking, chronic renal failure, autoimmune disease
and colonization with MRSA. Extended oral antibiotic pro-
phylaxis consisted of cefadroxil, 500 mg twice daily for
7 days, or 300 mg of clindamycin 3 times daily for 7 days if
they were allergic to cephalosporins. Patients who tested pos-
itive for MRSA received Bactrim DS twice daily for 7 days.
Infection rates before and after the oral antibiotic intervention
were compared as well as infection rates in high-risk patients
who did not receive extended oral antibiotics. High-risk pa-
tients without extended antibiotic prophylaxis were 4.9 (p =
0.009) and 4.0 (p = 0.037) times more likely to develop PJI
after TKA and THA, respectively, than high-risk patients with
extended prophylaxis.
Intraosseous Regional Administration of Antibiotics
Intraosseous regional administration (IORA) of antibiotics for
TKR has been evaluated in the preclinical and clinical set-
tings. Young et al. [34] used a mouse model with an intra-
articular knee prosthesis, followed by Staphylococcus aureus
inoculation to demonstrate that IORA prophylactic cefazolin
and vancomycin were more effective in reducing the number
of colony-forming units as compared with the same dose of
antibiotic given systemically.
The same group subsequently investigated the efficacy of
IORA in the setting of single-stage aseptic revision TKR [35].
Twenty patients were randomized to 1 g systemic IV prophy-
lactic vancomycin or a 500 mg vancomycin bolus injection
into the tibial via an intraosseous cannula under tourniquet
control prior to skin incision. Subcutaneous fat and bone sam-
ples were taken at regular intervals with tissue vancomycin
concentrations measured. IORA administration resulted in
vancomycin tissue concentrations 5 to 20 times higher than
systemic IV administration. High tissue concentrations were
maintained throughout the procedure despite periods of tour-
niquet deflation. There were no infections in either group.
IORA has also been investigated into context of primary
TKR for the obese patient. Chin et al. [36] using similar
investigative methods randomized 22 patients with a BMI >
35 undergoing TKA to receive either 15 mg/kg (maximum
2 g) IV vancomycin or 500 mg vancomycin via tibial IORA.
Mean concentrations in subcutaneous fat were measured with
39.3 mg/g in the IORA group and 4.4 mg/g in the IV systemic
group (p < 0.01). Mean tissue concentrations in bones were
34.4 mg/g in the IORA group and 6.1 mg/g in the IV systemic
group (p < 0.01). Two patients in the systemic group devel-
oped superficial infections, and no deep infections were re-
corded. Despite these promising results, as highlighted in a
2018 review, the effect of IORA on prosthetic joint infection
rates remains to be seen [37].
Intra-articular Dilute Antibiotic Lavage
The efficacy of topical antibiotics administered in irrigation
solution was investigated in a preclinical investigation by
Goswami et al. [38]. Cultures of Staphylococcus aureus
(S. aureus) and Escherichia coli (E. coli) were exposed for 1
and 3 min to irrigation solutions combined with polymyxin
and bacitracin, vancomycin or gentamycin. These solutions
were compared against dilute betadine, chlorhexidine,
Castile soap and sodium hypochlorite. After exposure, surviv-
ing bacteria were counted, and cytotoxicity was also assessed.
Irrigation with dilute polymyxin-bacitracin was ineffective
against both bacteria, vancomycin irrigation was effective
against S. aureus but not against E. coli, and gentamicin irri-
gation showed partial efficacy against E. coli but none against
S. aureus. Povidone-iodine, chlorhexidine and sodium hypo-
chlorite irrigation were effective against both S. aureus and
E. coli. Povidone-iodine showed the least cytotoxicity of the
efficacious solutions, and chlorhexidine lavage conferred the
greatest in vitro cytotoxicity. The authors concluded that di-
lute lavage with polymyxin-bacitracin adds little value and
that povidone-iodine lavagemay be a better wash due to lower
levels of cytotoxicity and potential antimicrobial resistance
associated with antibiotic lavage.
Wound Closure
Two recent meta-analyses have studied the rates of SSI with
staple as compared with suture skin closure. In a 2017 meta-
analysis, Kim et al. [39] included RCTs and high-quality ob-
servational cohort studies evaluating skin closure with sutures
or staples in primary TKR. Deep tissue closure techniques
were not considered. In terms of superficial infection rates, 7
studies reporting on 561 TKR were included. Of 232 knees
closed with sutures, 12 superficial infections were reported
(5.2%), compared with 8 events observed in 339 TKAs closed
with staples (2.4%). The difference was not statistially signif-
icant (RR, 1.78, p = 0.22). In terms of deep infection, 677
knees were included. There were 3 cases in 294 knees
(1.0%) closed with sutures and 1 in the 383 knees (0.3%)
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closed with staples. This was not statistically significant (RR,
3.78, p = 0.91). There were higher rates of prolonged wound
discharge in the staple group. The authors concluded that sta-
ples may have subtle clinical advantages over suture closure.
In a 2019 meta-analysis of RCTs by Krishnan et al. [40], the
authors included any study comparing compared sutures with
staples for skin closure after any orthopaedic surgery.
Although not specific to TJR, 6 of the 17 trials included only
patients undergoing elective THA or TKA. The authors con-
cluded that the existing RCTs do not provide definitive evi-




Ionic silver has been proposed as a topical antimicrobial by
preventing the growth of microorganisms. Its use in surgical
dressings has been explored in the arthroplasty setting. Grosso
et al., [41] retrospectively reviewed a single surgeon series of
1173 consecutive patients undergoing TKR or THR over an 8-
year period. After 4.5 years, sterile xeroform/gauze dressings
were changed to AQUACEL® Ag SURGICAL Dressing,
with no other major change in infection prevention. PJI within
3 months of surgery was diagnosed in 9 of 568 patients
(1.58%) managed with a sterile xeroform dressing and 2 of
605 patients (0.33%) with the use of AQUACEL® Ag
SURGICAL Dressing. Multiple logistic regression with con-
sideration to demographic factors, procedure factors and pa-
tient comorbidities found AQUACEL® Ag SURGICAL
Dressing as a protective factor for PJI (OR 0.092, p = 0.005).
Similar results have been reposted by Cai in a 2014 retrospec-
tive series [42]. In a prospective RCT by Kuo et al. [43], 240
patients were randomized to receive either AQUACEL Ag
Surgical Dressing or a Sofra-Tulle dressing after TKR.
Demographics were similar between groups. The incidence
of superficial SSI in the AQUACEL group was 0.8% (1 of
120) compared with 8.3% (10 of 120) in the control group
(p = 0.01). Only one patient in the Sofra-Tulle group devel-
oped a deep infection. Multivariate logistic regression demon-
strated that AQUACEL Ag Surgical Dressing was protective
against PJI with an odds ratio (OR 0.07, p = 0.01).
Outcomes of Bundled Infection Prevention
Interventions
The synergistic effect of combining multiple of the afore-
mentioned interventions has also been highlighted.
Matsen Ko et al. [44] reduced 12-month PJI rates in pri-
mary TJR from 1.4 to 0.37% over a 5-year period with
implementation of a bundled prevention strategy. This
bundled package was progressively implemented and in-
cluded staff education regarding PJI, minimization of op-
erating room traffic (all required items made available in
theatre, no intraoperative staff breaks), eliminating of lint-
producing materials; antimicrobial dressing left intact for
5 days, addition of vancomycin to cephalosporin prophy-
laxis, universal nasal mupirocin decolonization, preopera-
tive chlorhexidine wipes, post-operative bleeding reduc-
tion strategies (routine tranexamic acid and aspirin venous
thromboembolism prophylaxis where appropriate) and di-
lute betadine irrigation. Surgery was also postponed for
patients at high PJI risk (HbA1c > 7.5, BMI > 40, labora-
tory evidence of malnutrition) to allow for modification of
these risk factors or a proven effort to do so. Using a
bundled intervention with similar elements, Bullock
et al. [45] compared 90-day infection rates before and
after implementation. Comparing the 2 years before and
after implementation, there was a reduction in the THR
infection rate from 1.56 (10 of 641) to 0.59% (4 of 675);
however, this reduction was not statistically significant
(p = 0.09). There was, however, a statistically significant
reduction in TKR infection rate from 1.43 (13 of 908) to
0.11% (1 of 890) (p = 0.0016).
Conclusions
Strategies for infection prevention continue to evolve, and the
optimal infection prevention strategy in hip and knee
arthroplasty surgery is yet to be defined. The studies highlight-
ed in this review need to be interpreted within the context of
previous literature, and their limitations and biases need to be
carefully considered. Evolving strategies need to be continu-
ally tested rigorously in the clinical environment, but a multi-
modal approach and attention to detail are critical factors in
the prevention of prosthetic joint infection.
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